Interpace Biosciences, Inc.
IDXG
$0.95
$0.077.35%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 8.76M | 9.23M | 11.52M | 12.32M | 12.30M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8.76M | 9.23M | 11.52M | 12.32M | 12.30M |
| Cost of Revenue | 3.32M | 3.96M | 4.15M | 3.40M | 4.39M |
| Gross Profit | 5.44M | 5.28M | 7.37M | 8.92M | 7.90M |
| SG&A Expenses | 4.14M | 5.57M | 5.36M | 5.65M | 5.40M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.61M | 9.70M | 9.69M | 9.24M | 9.99M |
| Operating Income | 1.15M | -468.00K | 1.83M | 3.07M | 2.30M |
| Income Before Tax | 1.00M | -533.00K | 1.77M | 2.87M | 1.76M |
| Income Tax Expenses | -11.00K | -- | 18.00K | -8.00K | 4.00K |
| Earnings from Continuing Operations | 1.01M | -533.00K | 1.75M | 2.88M | 1.76M |
| Earnings from Discontinued Operations | -100.00K | -107.00K | -107.00K | 16.00K | -82.00K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 911.00K | -640.00K | 1.65M | 2.89M | 1.68M |
| EBIT | 1.15M | -468.00K | 1.83M | 3.07M | 2.30M |
| EBITDA | 1.26M | -367.00K | 1.92M | 3.17M | 2.39M |
| EPS Basic | 0.21 | -0.14 | 0.37 | 0.55 | 0.38 |
| Normalized Basic EPS | 0.14 | -0.08 | 0.25 | 0.41 | 0.25 |
| EPS Diluted | 0.04 | -0.14 | 0.06 | 0.05 | 0.38 |
| Normalized Diluted EPS | 0.02 | -0.08 | 0.04 | 0.04 | 0.25 |
| Average Basic Shares Outstanding | 4.43M | 4.42M | 4.42M | 4.41M | 4.39M |
| Average Diluted Shares Outstanding | 27.70M | 4.42M | 27.70M | 49.72M | 4.42M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |